De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study
Table 1
Clinicopathological characteristics of patients before and after propensity score matching.
Variables
Before propensity score matching
After propensity score matching
Low AST/ALT ()
High AST/ALT ()
value
Low AST/ALT ()
High AST/ALT ()
value
Mean age (year)
<0.001
0.001
Gender
<0.001
<0.001
Female
45 (9.6%)
74 (24.3%)
31 (10.2%)
74 (24.3%)
Male
421 (90.4%)
231 (75.7%)
274 (89.8%)
231 (75.7%)
BMI (kg/m2)
<0.001
0.067
ASA
0.373
0.714
1
172 (36.9%)
103 (33.7%)
110 (36.0%)
103 (33.7%)
2
275 (59.0%)
182 (59.7%)
180 (59.0%)
182 (59.7%)
≥3
19 (4.1%)
20 (6.6%)
15 (4.9%)
20 (6.6%)
Operative type
0.218
0.273
Open
424 (91.0%)
285 (93.5%)
295 (93.4%)
285 (93.5%)
Laparoscopic
24 (5.2%)
16 (5.2%)
11 (3.6%)
16 (5.2%)
Robot
18 (3.8%)
4 (1.3%)
9 (3.0%)
4 (1.3%)
Diversion type
0.052
0.168
Conduit
253 (54.3%)
194 (63.6%)
209 (68.5%)
194 (63.6%)
Neobladder
213 (45.7%)
111 (36.4%)
96 (31.5%)
111 (36.4%)
Tumor grade
0.396
0.569
Low
12 (2.6%)
11 (3.6%)
10 (3.3%)
11 (3.6%)
High
454 (97.4%)
294 (96.4%)
295 (96.7%)
294 (96.4%)
Tumor size (cm)
0.017
0.058
Pathological T stage
0.002
0.112
T1
73 (15.7%)
57 (18.7%)
53 (17.4%)
57 (18.7%)
T2
264 (56.7%)
122 (40.0%)
156 (51.0%)
122 (40.1%)
T3
106 (22.7%)
104 (34.1%)
80 (26.2%)
104 (34.1%)
T4
23 (4.9%)
22 (7.2%)
16 (5.2%)
22 (7.2%)
Margin positive
7 (1.5%)
15 (4.9%)
0.036
5 (1.6%)
15 (4.9%)
0.041
LVI
129 (27.6%)
106 (34.8%)
0.055
90 (29.5%)
106 (34.8%)
0.193
CIS
155 (33.3%)
97 (31.8%)
0.735
97 (31.8%)
97 (31.8%)
1.000
Pathological N stage
0.455
0.544
N0
382 (82.0%)
240 (78.7%)
252 (82.6%)
240 (78.7%)
N1
34 (7.3%)
20 (6.6%)
20 (6.6%)
20 (6.6%)
N2
42 (9.0%)
38 (12.5%)
28 (9.2%)
38 (12.5%)
N3
8 (1.7%)
7 (2.3%)
5 (1.6%)
7 (2.3%)
Removed LN
0.018
0.158
Positive LN
0.199
0.146
Pathological M stage
0.749
0.966
M0
462 (99.2%)
304 (99.7%)
363 (99.2%)
304 (99.7%)
M1
4 (0.8%)
1 (0.3%)
2 (0.7%)
1 (0.3%)
NACH
64 (13.7%)
39 (12.8%)
0.827
40 (13.1%)
39 (12.8%)
0.976
ACH
99 (21.2%)
74 (24.3%)
0.414
65 (21.3%)
74 (24.3%)
0.440
ART
4 (0.8%)
3 (1.0%)
0.986
3 (1.0%)
3 (1.0%)
1.000
Recurrence rate
139 (29.8%)
115 (37.7%)
0.037
89 (29.2%)
115 (37.7%)
0.032
Mortality
141 (30.3%)
140 (45.9%)
<0.001
96 (31.5%)
140 (45.9%)
<0.001
Cancer-caused mortality
88 (18.9%)
96 (31.5%)
<0.001
59 (19.3%)
96 (31.5%)
0.001
AST/ALT ratio
<0.001
<0.001
ASA: American Society of Anesthesiologists; BMI: body mass index; NACH: neoadjuvant chemotherapy; ALT: alanine aminotransferase; AST: aspartate aminotransferase; LVI: lymphovascular invasion; CIS: carcinoma in situ; LN: lymph node; NACH: neoadjuvant chemotherapy; ACH: adjuvant chemotherapy; ART: adjuvant radiotherapy.
